Every 424B that Tvardi Therapeutics, Inc. (TVRD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TVRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVRD filings page.
Tvardi Therapeutics, Inc. is launching an at-the-market equity program to sell up to $9,689,765 of common stock through JonesTrading under an existing Capital on Demand Sales Agreement. JonesTrading will act as sales agent on a commercially reasonable efforts basis and receive up to 3.0% of gross proceeds as commission.
The company’s non‑affiliate float is valued at $62,208,945 under General Instruction I.B.6 of Form S‑3, and it has sold about $11.0 million of stock in the prior twelve months under this rule. Assuming sales at $3.08 per share, up to 3,146,027 new shares could be issued, increasing shares outstanding from a pro forma 12,492,113 to up to 15,638,140 and causing an illustrated dilution of $0.91 per share. Net proceeds are intended for general corporate purposes, including clinical trial, research and development, general and administrative expenses, capital expenditures and potential in‑licensing or acquisitions.
Tvardi Therapeutics (TVRD) files a prospectus supplement registering the resale of up to 2,084,117 shares of common stock by selling stockholders pursuant to the Merger Agreement. The supplement attaches portions of the Form 10-K for the fiscal year ended December 31, 2025, and updates disclosure with clinical and corporate information.
The 10-K describes Tvardi’s pipeline focused on direct STAT3 inhibitors (TTI-101 and prodrug TTI-109), clinical programs in IPF and HCC, Phase 1 and Phase 2 trial details, IND acceptance for TTI-109, certain preclinical findings, patent and license arrangements with Baylor College of Medicine, and corporate reorganizations following the Merger. Shares outstanding were 9,381,344 as of March 26, 2026.
Tvardi Therapeutics files a prospectus supplement for the resale of up to 2,084,117 shares of common stock. The supplement updates the prospectus dated November 8, 2025 with information from Current Reports on Form 8-K filed December 18, 2025 and March 6, 2026. The resale shares were issued to certain selling stockholders pursuant to the Merger Agreement dated December 17, 2024.
The supplement states the Nasdaq last reported sale price was $4.02 on March 5, 2026. The supplement also attaches excerpts of two 8-Ks disclosing retention option grants, a severance and change-in-control plan, and the company’s 2026 annual meeting date and proxy submission deadlines.
Tvardi Therapeutics, Inc. filed a prospectus supplement covering the resale by certain selling stockholders of up to 2,084,117 shares of common stock issued under the December 17, 2024 Merger Agreement with Cara Therapeutics. The supplement updates the base prospectus with information from the company’s Q3 2025 Form 10‑Q.
The common stock trades on Nasdaq as “TVRD.” The last quoted sale price on November 12, 2025 was $4.24. Shares outstanding were 9,381,344 as of November 10, 2025.
The attached 10‑Q reports a net loss of $5.5 million for the quarter and $10.9 million for the nine months ended September 30, 2025, cash and cash equivalents of $21.4 million and short‑term investments of $15.0 million. Management states that conditions raise substantial doubt about the company’s ability to continue as a going concern. The 10‑Q also notes preliminary Phase 2 data in IPF for TTI‑101 did not meet study goals, with further analyses ongoing.